Back to companies

Intra-Cellular Therapies Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Intra-Cellular Therapies Inc (ICTI) is a biopharmaceutical company that discovers and develops and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders. The company pipeline includes lumateperone for the treatment of major depressive disorder and bipolar depression and TI-1284-ODT-SL for the treatment of agitation and psychosis in patients with Alzheimer’s. ICTI's other pipeline includes PDE inhibitor for Parkinson’s and cancer immunotherapy and ITI-333 for opioid use disorder, pain and mood disorders. It also utilizes CNSProfile, a technology platform that monitors the phosphoprotein changes elicited by major psychotropic drug classes and subclasses and generates a unique molecular signature for drug compounds. ICTI is headquartered in New York, the US.

Gain a 360-degree view of Intra-Cellular Therapies Inc and make more informed decisions for your business Gain a 360-degree view of Intra-Cellular Therapies Inc and make more informed decisions for your business Contact Us
Headquarters United States of America

Address 430 East 29th Street, Suite 900, New York, 10016


Telephone 1 646 4409333

No of Employees 610

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange ITCI (NASD)

Revenue (2022) $464.4M 85.5% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 45.5% (2022 vs 2021)

Market Cap* $7.2B

Net Profit Margin (2022) XYZ 70.6% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

Intra-Cellular Therapies Inc premium industry data and analytics

60+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Intra-Cellular Therapies Inc’s relevant decision makers and contact details.

60+

Catalyst Calendar

Proactively evaluate Intra-Cellular Therapies Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Clinical Trials

Determine Intra-Cellular Therapies Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

16+

Pipeline Drugs

Identify which of Intra-Cellular Therapies Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

6

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Intra-Cellular Therapies Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Intra-Cellular Therapies Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline CNSProfile
Lumateperone - major depressive disorder, MDD and Bipolar Depression CAPLYTA
TI-1284-ODT-SL - Alzheimer’s (Agitation, Psychosis) and Generalized Anxiety Disorder
XYZ
XYZ
XYZ
Understand Intra-Cellular Therapies Inc portfolio and identify potential areas for collaboration Understand Intra-Cellular Therapies Inc portfolio and identify potential areas for collaboration Contact Us
Image for loader

Competitor Comparison

Key Parameters Intra-Cellular Therapies Inc Supernus Pharmaceuticals Inc Axsome Therapeutics Inc Concert Pharmaceuticals Inc Intellect Neurosciences Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City New York Rockville New York Lexington Englewood Cliffs
State/Province New York Maryland New York Massachusetts New Jersey
No. of Employees 610 652 545 - -
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Sharon Mates Ph.D Chairman; Chief Executive Officer; President Executive Board 2002 70
Lawrence J. Hineline Assistant Secretary; Chief Financial Officer; Senior Vice President - Finance; Treasurer Senior Management 2013 66
Karen Sheehy Chief Compliance Officer; Senior Vice President Senior Management - -
Suresh Durgam Chief Medical Officer; Executive Vice President Senior Management 2020 54
Michael Halstead President Senior Management 2024 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Intra-Cellular Therapies Inc key executives to enhance your sales strategy Gain insight into Intra-Cellular Therapies Inc key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer